The aim of the present study was to investigate whether the early changes in the immune system observed after ABMT would persist over years. 
and function within the first months following ABMT. In contrast, the CD4 ϩ T lymphocytes have been found not to recover completely, even as long as 2 years post transplant in many adult patients. 4 The persisting subnormal CD4 ϩ T cell counts and CD4/CD8 ratios may put patients at risk of developing opportunistic infections and even recurrence of their malignancy. The changes in the immune system over the first few months and years after ABMT and PBSCT have been extensively studied. 5, 6 It is, however, still an open question whether complete normalization of CD4
ϩ T cells will occur in these patients.
The role of purging bone marrow or peripheral progenitor cells remains a controversial issue. It is not clear whether purging is of clinical benefit to the patient. Furthermore, purging may influence the recovery of lymphoid cells post transplant. 7 In the present study we investigated immunological recovery in an unselected population of lymphoma patients, including 36 out of 46 patients in complete remission who received ABMT in Norway between April 1987 and December 1993. Nearly all the patients were treated with a TBI-containing conditioning regimen supported by purged autologous bone marrow. Our data indicate that changes in the immune system previously reported early after ABMT persist even 4-10 years post-transplant.
Materials and methods

Patients and controls
From April 1987 to December 1993 all 85 cases of malignant lymphoma requiring ABMT in Norway were treated at the Norwegian Radium Hospital. In January 1997, 46 patients were alive and in complete remission (CR) and 39 of these agreed to participate in this study. Three patients were withdrawn from the examination due to: an intra-cranial insult; another was hospitalized with a severe bacterial infection and myelodysplasia and the third had psychological problems. Thus, 36 patients were enrolled. The median age was 39.5 years (18-59 years) and median time since ABMT was 5 years (4-10 years). Twenty-eight patients received bone marrow purged by monoclonal antibodies and magnetic beads. This method is described elsewhere. 8, 9 Each patient was compared with an age-and sex-matched control recruited from blood donors. Patient characteristics are summarized in Table 1 . 
Reagents/Antibodies
Phorbol-12-myristate 13-acetate (PMA), ionomycin and brefeldin-A (BFA) were purchased from Sigma (St Louis, MO, USA). MoAbs which were used in flow cytometry were FITC-conjugated anti-CD3, -CD4, -CD16, -CD45, -CD45RO, -kappa, and -lambda; PE-conjugated anti-CD8, -CD14, -CD19, -CD20, -CD45RO, -CD45RA, -CD69, -IL-4, and -IFN-␥; PerCP-conjugated anti-CD3 and -CD4. All antibodies were obtained from Becton Dickinson (San Jose, CA, USA)/PharMingen (San Diego, CA, USA).
Immunophenotyping
A complete blood count including differentials, was performed within 6 h after drawing of EDTA anticoagulated blood. Within 24 h, whole blood was used for immunophenotyping. For most samples, antibodies were added to whole blood. After incubation, the erythrocytes were lysed and the samples run in the flow cytometer without further washing. When testing for immunoglobulin light chains on B lymphocytes, the erythrocytes were lysed and the sample washed before staining. Two-color data were acquired on FACSscan flow cytometer equipped with a 488 nm argon laser (Becton Dickinson). A tight light scatter gate was drawn around the lymphocytes and these cells were analyzed using CellQuest software on a Power Macintosh computer. Counts of B cells (CD20 ϩ ), T cells (CD3 ϩ ), CD4 ϩ and CD8 ϩ cells were calculated, using the total lymphocyte count and the percentage of cells with the different phenotypes. The CD4CD8 double-positive group generally constituted a small population (Ͻ3%) of the cells and was not counted. The CD4/CD8 ratio was calculated.
Intracellular cytokine analysis
PBMC from patients and controls were separated from whole blood using vacutainer cell preparation tubes (CPT; Becton Dickinson). Cells were washed twice in PBS with 0.1% BSA, and resuspended at 2 × 10 6 cells/ml in RPMI-1640 supplemented with 5% AB serum, streptomycin and penicillin. The cells were stimulated for 4 h with PMA (25 ng/ml) and ionomycin (500 ng/ml) in the presence of brefeldin-A (10 g/ml), an inhibitor of protein secretion inducing cytoplasmic accumulation of cytokines. This technique was originally described by Jung and co-workers, 10 modified by Picker et al. 11 Cultured cells were washed twice in PBS with BSA and stained with MoAbs to the following cell-surface markers: CD3, CD4 and CD45RO. The cells were then fixed and permeabilized with FACS permeabilizing solution according to the manufacturer's instruction (FastImmune Kit; Becton Dickinson), followed by staining with MoAbs specific for IL-4 or IFN-␥.
The samples were analyzed on a FACScan flow cytometer using Lysis II or CellQuest software (Becton Dickinson) on HP 340 or Macintosh Quadra workstation. A tight light scatter gate was drawn around the major lymphocyte population. Cells in this gate, staining double positive for CD4 and CD3, or double positive for CD4 and CD45RO were studied. Ten thousand events were acquired and analyzed from each sample.
Statistical methods
For comparison of unpaired data between two groups the Mann-Whitney U test was applied. Kruskal-Wallis oneway analysis of variance was used for comparison between several groups. Coefficients of correlation were calculated by the Spearman rank test. Data are given as medians and ranges if not otherwise stated. P values are two-sided and considered significant when Ͻ0.05.
Results
Median counts of peripheral blood cell
There was no significant difference between patients and controls in numbers of leukocytes, thrombocytes or red blood cells. The numbers of granulocytes were similar, but the numbers of monocytes and lymphocytes were lower in patients ( Table 2 /l in patients and 0.87 × 10 9 /l in controls (Figure 1a) . A tendency towards higher CD4 counts in patients transplanted 7-10 years ago (0.57 × 10 9 /l) compared to patients transplanted 4-6 years ago (0.47 × 10 9 /l), was observed. Due to low CD4 ϩ cell number, the CD4/CD8 ratio was significantly lower among ABMT patients (0.8) than controls (1.6) ( Table 2) .
Expression of CD45 isoforms on CD4
ϩ T cells Naive CD4 ϩ T cells generally express the high molecular weight CD45 isoform, CD45RA, whereas memory CD4 ϩ T cells have the low molecular weight isoform CD45RO. The transplanted patients had a significantly lower fraction of CD4 ϩ CD45RA ϩ cells compared with controls, 19.5% vs 38% (Figure 1b) . The fraction of CD4 ϩ CD45RO ϩ cells was higher in patients (76%) than controls (54%) (Figure 1c) . In the control group we found a correlation between increasing age and decreasing fraction of CD45RA ϩ cells, whereas in patients there was no such correlation ( Figure 2 ).
Immune reconstitution and bone marrow purging
Twenty-eight of 36 patients received bone marrow purged by negative selection using MoAbs to B cell antigens (20 patients) or T cell antigens (eight patients) and immunomagnetic beads. There were no significant differences in counts of CD4 ϩ cells, or CD8 ϩ cells observed between patients who received T cell-depleted (eight patients), B cell-depleted (17 patients), or unpurged bone marrow (six patients) (Table 3) .
Immunophenotyping was successful in three out of five patients with Hodgkin's lymphoma. Numbers of T cells were not lower among these patients. Due to small numbers of patients with different subtypes of lymphoma, results comparing different groups are not presented.
Production of intracellular cytokines
Cells from both patients and controls were successfully stimulated by PMA and ionomycin detected by CD69 expression in more than 90% of the CD4 ϩ CD3 ϩ cells. There was a significant difference between patients and controls in the percentage of CD4 ϩ CD3 ϩ cells producing IFN-␥ or IL-4 after stimulation. In the ABMT group 31.9% (10.2-66.2%) of CD3 ϩ CD4 ϩ cells produced IFN-␥, compared to 15.9% (3.7-32.2%) in the control group (Figure 3) . A similar and even larger difference was observed regarding production of IL-4 by CD3 ϩ CD4 ϩ cells, 6.9% (0.8-16.6%) vs 1.1% (0.1-14.1%). The patients had a higher fraction of cells of the CD4 ϩ CD45RO ϩ phenotype. To investigate whether over-representation of these cells could explain the difference in cytokine profile, we selectively looked at production of cytokines in the CD4 ϩ CD45RO ϩ subset. The differences became less pronounced but were still significant. Thirty-five percent (14.4-69.9%) in patients vs 25% (4.2-33.9%) in controls produced IFN-␥, and 6.8% (1.3-27.1%) vs 1.7% (0.5-11.2%) produced IL-4 ( Figure 3 ).
Discussion
It has been a consistent finding that the numbers of NK cells, B lymphocytes and CD8 ϩ T lymphocytes return to normal levels within the first months following ABMT. In contrast, CD4 ϩ T lymphocytes remain subnormal for a longer time period. This generally results in a decreased CD4/CD8 ratio for at least 2 years post transplant. 12, 13 Similar results have been reported in patients undergoing intensive chemotherapy without bone marrow or stem cell support.
14, 15 Pedrazzini and colleagues 4 reported that only 14 out of 79 ABMT patients had recovered to 40% of normal CD4 ϩ T cell counts at a median follow-up of 24 months. They estimated the time to recovery of normal levels of CD4 ϩ cells to be 3-4 years or more. Our data with a median follow-up of 5 years show that the CD4 ϩ counts still remain low, at approximately 2/3 of control levels. We observed a tendency towards higher CD4 counts among those who were transplanted 7-10 years earlier compared to the patients transplanted 4-6 years earlier. This difference was not significant, but might indicate that the process towards normalization of this population of cells continues even after many years. CD4 ϩ T lymphocytes generally express either a CD45 high molecular weight isoform, CD45RA, or a low molecular weight isoform CD45RO. The CD4 ϩ CD45RA ϩ cells are regarded as 'naive' T cells recently issued from the thymus, whereas the CD4 ϩ CD45RO ϩ population responds to recall antigens and represents 'memory' cells. 17 However, a new model for immunological memory has recently been presented, postulating that 'memory' T cells can revert from the CD4 ϩ CD45RO ϩ to the CD4 ϩ CD45RA 'naive' phenotype in the absence of antigen. 18 Previous reports have shown that the CD4 ϩ CD45RA ϩ subset is markedly reduced during the first months following ABMT and recovers slowly. 5, 19 Hakim and co-workers 15 clearly demonstrated that these cells are more sensitive to chemotherapy; their numbers dropped severely during and after treatment in breast cancer patients receiving the FLAC (5-FU, leucovorin, doxorubicin, cyclophosphamide) regimen. After 1 year the number of CD4 ϩ CD45RA ϩ cells remained less than one third of pretreatment levels. The CD4 ϩ CD45RO ϩ subset showed only a modest decrease and recovery was faster. Our results show that even 4-10 years after ABMT, the percentage of CD4 ϩ CD45RA ϩ cells accounted for 19.5% of CD4 ϩ cells in patients compared to 38% in controls. On the other hand, the CD4 ϩ CD45RO ϩ subset was increased in the ABMT group. Maturation of T cells has been shown to decrease as early as in young adulthood due to involution of the thymus. It has been postulated that this prohibits the regeneration of naive CD4 ϩ CD45RA ϩ cells after ABMT. 20 In the non-transplant setting Mackall and colleagues 21 observed that in adult patients, depletion of CD4 ϩ T cells was prolonged, compared to pediatric patients. This suggested an inverse correlation between age and the ability to regenerate 'naive' T cells. Mackall and colleagues 22 have recently published data from mouse models showing that involuted thymuses from aged animals could regenerate a significant number of T cells. They argue that accumulation of 'memory' type CD4 ϩ cells after bone marrow transplantation is not only caused by reduced thymic function in adults, but also increased antigen-driven peripheral expansion of naive CD4 ϩ CD45RA ϩ thymic emigrants into the CD4 ϩ CD45RO subset. Our data confirm that the imbalance between the subsets of CD4 ϩ cells persists for many years after ABMT, and it is still an open question whether normal numbers of the naive and memory CD4 ϩ T cells can ever be restored. CD4 ϩ T cells produce different cytokines, and based on the production profiles two functionally different subgroups, Th1 and Th2, can be defined. Th1 cells mainly produce IFN-␥, IL-2 and TNF-␣, whereas Th2 cells produce IL-4, IL-5 and IL-10. 23 Guillaume et al 24 and others 25 have reported a defect in the production of several cytokines, particularly IL-2, early after ABMT. In our study a higher proportion of CD4 ϩ T cells produced IL-4 or IFN-␥ after stimulation with PMA and ionomycin in ABMT patients than in controls. Previous studies have indicated that IFN-␥ and IL-4 are mainly produced by the CD45RO ϩ fraction of T cells. 11, 26 When adjusting for the higher fraction of CD4 ϩ
CD45RO
ϩ cells in our patients, the difference became less, but was still significant. The reduced number of CD4 ϩ CD45RA ϩ cells does not necessarily indicate immune competence, the diversity of the T cell repertoire might be equally or more important. Jerne 27 postulated that 10% of the total repertoire is sufficient for immune competence. Thus, our patients might be immune reconstituted despite a low number of CD4 ϩ T cells. The most physiological stimulation of T cells appears to occur via the T cell receptor (TcR) in the presence of an antigen presenting cell. PMA and ionomycin stimulate all T cells regardless of their TcR specificity. Functional studies of lymphocytes several years post-ABMT are scarce. As far as we know, our study is the first to investigate intracellular cytokine production at this time point. The data indicate that a higher fraction of CD4 ϩ T cells post ABMT are activated and/or have differentiated to become Th1 or Th2 cells. The three to four times increase in IL-4 producing cells compared to a 50% increase in IFN-␥ producing cells in patients indicates a dominant Th2 response, at least after stimulation with PMA and ionomycin. Th2 cells are responsible for induction of humoral immunity. We found that serum levels of IgG, IgA and IgM were normal in patients (data not shown). However, the numbers of B cells were increased. The increase in fractions of Th1 and Th2 cells in patients post-ABMT could explain why serious opportunistic infections were rare (patient self reported questionnaire, data not shown), even though the counts of CD4 ϩ cells were significantly less that observed in controls. The patient material in this study is of particular interest, because the bone marrows were purged by negative selection in most cases, using monoclonal antibodies and immunomagnetic beads. Furthermore, all except three patients received a conditioning regimen containing TBI (13 Gy) and cyclophosphamide (120 mg/kg). This regimen is probably more effective in destroying residual T cells and B cells in the host than are other regimens based on combination chemotherapy. Anderson and co-workers 28 reported that patients who underwent T cell-depleted ABMT had a profound immunodeficiency not reflected in their phenotypic reconstitution. Pedrazzini et al 4 reported that purging autologous marrow with monoclonal antibodies to B cell antigens delayed B cell recovery. Keever et al 7 found only modest quantitative and temporal differences in immune reconstitution in recipients of T celldepleted marrow compared to recipients of conventional marrow grafts. We could not find any significant differences between patients who received B or T cell-depleted or unpurged bone marrow in median counts of B cells, CD4 ϩ cells, CD8 ϩ cells. Patient numbers are low, but the data indicate that lymphocytes present in the graft may play a minor role in the long-term immune reconstitution of these patients.
In conclusion, lymphoma patients in complete remission 4-10 years after ABMT have a markedly reduced number of CD4 ϩ T cells, and especially the CD4 ϩ CD45RA
ϩ 'naive' T cell compartment. In addition, a larger fraction of the CD4 ϩ T cells produce IFN-␥ or IL-4 upon stimulation with PMA and ionomycin, suggesting functional differences compared to normal controls.
